SLC5A2 and congestive heart failure: This led to the more recent clinical trials that have dramatically changed the paradigm and guidelines for treating CVD, and CHF (congestive heart failure) in particular, with SGLT2 (sodium-glucose cotransporter-2) inhibitors of note.